New combo aims to wipe out hidden ovarian cancer cells
NCT ID NCT05739981
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 26 times
Summary
This study tests whether adding an experimental drug (IMNN-001) to standard chemotherapy and bevacizumab can better eliminate tiny leftover cancer in people with newly diagnosed advanced ovarian, fallopian tube, or peritoneal cancer. About 30 participants will be randomly assigned to receive either the standard treatment alone or with IMNN-001. The main goal is to see if the combination leads to less residual disease seen during a second-look laparoscopy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins Medicine SKCCC
COMPLETEDBaltimore, Maryland, 21231, United States
-
Memorial Sloan Kettering Cancer Center
ACTIVE_NOT_RECRUITINGNew York, New York, 10065, United States
-
OU Health, Stephenson Cancer Center
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact Email: •••••@•••••
Contact
-
University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.